Clinical trial
Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in…
NCT00102804 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00102804 |
|---|---|
| Title | Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment for Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | Pemetrexed, Placebo, Best Supportive Care |
| Enrollment | 663 |
| Start date | Mar 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Dec 1, 2013 |
| First posted | Feb 2, 2005 |
| Last update posted | Dec 29, 2014 |
| Countries | Australia, Austria, Brazil, Bulgaria, China, Croatia, Czechia, Germany, Greece, Hungary, India, Italy and 8 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: